Fig. 6.

Efatutazone treatment downregulates Akt phosphorylation in MCFDCIS xenograft tumors. a Representative western blots showing phospho-Akt (Ser 473), Akt, and b phospho-ERK1/2 (Thr202/Tyr204), ERK1/2, and actin expression in protein lysates obtained from MCFDCIS xenograft tumors treated 3 weeks with vehicle or 30 mg/kg efatutazone (left panels). The ratio of phospho-Akt to total Akt and phospho-ERK1/2 to total ERK1/2 was quantified using Fiji (right panels). Mean ± SEM (Student’s t test; n = 8; *p < 0.05 vs vehicle)